Waystar: Profitable Growth, but the Price Demands More

The Quarter in Context

Waystar’s second-quarter revenue was $319.7 million, up 18.1% from $270.7 million a year earlier. Operating income was $76.0 million, up 17.3%, while net income reached $40.9 million, up 27.0%. Diluted earnings per share were $0.21, compared with $0.18. The operating margin was 23.8%, slightly below the prior-year quarter’s 24.0%, so profit grew broadly in line with revenue rather than through notable margin expansion.

Cash flow presents a more mixed picture. Reported operating cash flow for the quarter was $59.4 million, derived by subtracting first-half operating cash flow from the six-month figure. Capital expenditure in the quarter was similarly derived at $16.1 million, producing a calculated accounting free-cash-flow proxy of $43.3 million. For the six months, operating cash flow fell to $144.3 million from $161.0 million even as net income rose, while purchases of property, equipment, and internally developed software increased to $31.4 million from $11.2 million.

The quarter therefore supports two conclusions. First, Waystar is growing profitably, not merely reporting revenue growth. Second, cash conversion and reinvestment need closer attention: the filing says higher investing cash use reflected both investment securities activity and more property-and-equipment purchases, but it does not separate maintenance spending from growth spending. The dated share price was $28.85 on October 26, 2026, giving Waystar a market capitalization of $5.53 billion.

Business Model and Profit Engine

Waystar provides mission-critical cloud technology to healthcare organizations. Its platform manages the healthcare-payment process from pre-service engagement through remittance and reconciliation. Healthcare providers are the direct customers: they pay for software and related services that improve claim accuracy, reduce manual work, accelerate reimbursement, and provide visibility into cash collection. The ultimate economic demand comes from providers seeking more efficient and accurate payment processing; payers and patients participate in the transaction flow, but the filing identifies providers as Waystar’s clients.

Filing fact: Waystar reports one consolidated revenue line, so the available evidence does not quantify revenue or profit by product, channel, customer segment, recurring versus transactional treatment, or geography. It also does not disclose contract duration, pricing mechanics, customer concentration by revenue, renewal rates, backlog, or unit economics. Those are material data gaps, not evidence that all revenue is recurring or all pricing is favorable. The company defines net revenue retention, but its numerical value and related discussion are not present in the cited excerpts.

Analytical inference: A cloud platform embedded in payment workflows may have recurring characteristics because healthcare providers need continuous claim and remittance processing, but the available filing does not establish what proportion is subscription, usage-based, implementation, or other service revenue. “Mission-critical” describes the company’s characterization of its role; it is not, by itself, proof of contractual switching costs. Observable conditions that would weaken the profit engine include falling net revenue retention, shorter contract terms, rising implementation costs, customer consolidation, or pricing concessions that prevent revenue growth from translating into operating leverage.

The profit bridge is visible at the consolidated level. Q2 revenue less cost of revenue produced $222.0 million of gross profit, derived from the filing. Sales and marketing, general and administrative, research and development, and depreciation and amortization then consumed $145.9 million, leaving $76.0 million of operating income. Software development, service delivery, sales, administration, and amortization are partly fixed over shorter periods, while revenue-linked hosting, support, or transaction costs may vary; the filing does not provide enough detail to quantify that split or measure incremental margins.

Capital intensity appears moderate at the operating level, but working capital and acquisition-related balances matter. At June 30, 2026, accounts receivable were $185.9 million and deferred revenue was $67.6 million across current and long-term balances. Six-month operating cash flow included a $10.9 million use from receivables and a $5.7 million use from deferred revenue. Goodwill of $4.01 billion and intangible assets of $1.22 billion exceeded stockholders’ equity of $3.99 billion, making tangible book value negative.

Earnings Quality and Cash Conversion

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing. They are calculations from SEC facts rather than separately reported quarterly line items.

Reported earnings are GAAP-based, and the income statement shows no unusual tax item dominating the quarter. Income before taxes was $56.4 million, income tax expense was $15.5 million, and net income was $40.9 million. This means the earnings increase is not explained by a discrete tax benefit in the quarter. Interest expense was $18.6 million, plus $1.0 million of related-party interest expense, which materially reduced operating income before tax.

The principal earnings-quality issue is the divergence between profit growth and cash generation. For the first six months, net income rose 36.9% to $84.2 million, while operating cash flow declined 10.4% to $144.3 million. The cash-flow reconciliation included $25.2 million of stock-based compensation, $82.9 million of depreciation and amortization, and a $36.7 million deferred-tax adjustment. The deferred-tax movement is a timing difference in reconciling accounting income to cash taxes, while stock-based compensation is a non-cash expense but an economic cost through dilution.

For the first half, operating cash flow of $144.3 million less $31.4 million of property, equipment, and internally developed software purchases produced a calculated accounting free-cash-flow proxy of $112.9 million. This is not “maintenance-capex owner earnings,” because the filings do not identify how much capital spending is required merely to maintain the business. It also includes no adjustment for stock-based compensation; adjusted for dilution, the economic owner cash yield would be lower than the headline proxy.

The full trailing period provides a more useful, though still imperfect, cash baseline. TTM operating cash flow was $293.0 million and TTM capital expenditure was $46.7 million, yielding a $246.3 million accounting free-cash-flow proxy. That proxy starts from a company with $12.6 million of cash and $1.47 billion of total debt, so it should not be confused with cash available for distributions after debt service or shareholder returns.

Cash conversion should improve if higher earnings become cash and capital spending normalizes. Conversely, a continued gap between net income and operating cash flow, particularly if caused by receivable growth, deferred-cost investment, or elevated capitalized software spending, would weaken the earnings thesis.

Business Quality, Moat, and Industry Position

Waystar sits in enabling infrastructure for healthcare payments, between providers that receive payments and the broader payer, patient, and clearing-network ecosystem. Its direct customers are healthcare organizations; their final demand is accurate and timely reimbursement. Value capture comes through software and services that reduce manual tasks and improve payment accuracy. This is strategically important because payments are a core administrative process, but strategic importance alone does not establish excess returns on capital.

Observable evidence of potential durability includes a growing consolidated revenue base, positive operating income, meaningful research and development spending, and the stated ability of the platform to integrate across complex healthcare workflows. The company also describes its offering as mission-critical and says the market includes the United States, Puerto Rico, and other U.S. territories. These facts support the existence of a functioning platform and a broad addressable customer setting, but they do not establish a dominant market position.

Supply-chain inference: Waystar is a downstream enterprise-software participant and an enabling intermediary in the healthcare-payment chain. It depends on third-party infrastructure and vendors and operates in a highly competitive industry. The filing identifies interoperability with client and vendor systems, implementation timing, client retention, selling cycles, and acquisition integration as business risks. These factors constrain how much of the customer’s savings Waystar can capture.

The bottleneck classification is important participant, with a score of 3 out of 5. Embedded workflows and regulated data may create qualification and switching friction, but the evidence does not show scarce capacity, low substitutability, supplier concentration, strong order visibility, or a monopoly-like position. Pricing power cannot be confirmed because contract structure and unit economics are unavailable. A durable advantage would be better demonstrated by sustained retention, stable or rising margins despite customer additions, low implementation disruption, and limited customer concentration.

The June 2026 cybersecurity incident is a direct test of trust and moat. Waystar reported unauthorized acquisition of source-code copies and inactive data from one application, including protected health information associated with fewer than 1% of clients. The filing says production systems and active client data were not accessed, but the investigation and potential client or regulatory consequences were incomplete.

Management and Capital Allocation

Observable management conduct is mixed. The company increased research and development spending to $17.7 million in Q2 from $12.6 million, consistent with reinvestment in product capability, though the filing does not state which projects produced the increase. It also spent $31.4 million on property, equipment, and internally developed software in the first half, but the purpose and maintenance-versus-growth split are not disclosed.

Capital allocation changed materially in Q2. The board authorized a $200 million repurchase plan, and Waystar bought 659,061 shares for $12.7 million at an average price of $19.24. The plan is to be funded from working capital. Because the company carried $1.47 billion of total debt and only $12.6 million of cash at June 30, buying stock while borrowing costs remain high is not automatically value-accretive. The low purchase price is a fact, not proof that the shares were undervalued.

Equity issuance also matters. The company issued 995,844 shares under employee plans in the first six months and recorded $25.3 million of stock-based compensation. Diluted weighted-average shares in Q2 were 194.5 million, 7.1% above the prior-year quarter. Repurchases partly offset issuance, but per-share growth remains less impressive than aggregate profit growth.

A leadership transition adds uncertainty. Alpana Wegner became CFO effective August 1, 2026, succeeding Steven Oreskovich, who agreed to provide advisory services through June 2027. The filing discloses no disagreement or internal-control issue, so the departure is not evidence of misconduct. Nevertheless, a new CFO during rapid growth and elevated investment is a period requiring closer capital-allocation and disclosure scrutiny.

Valuation and What the Market Already Expects

As of October 26, 2026, Waystar’s market capitalization was $5.53 billion and the share price was $28.85. The TTM accounting free-cash-flow proxy of $246.3 million gives the equity a cash-flow yield of about 4.5% before considering the balance-sheet bridge. That is a demanding starting yield for a leveraged healthcare software company whose cash conversion weakened in the latest half-year.

The enterprise-to-equity bridge matters. At June 30, 2026, Waystar had $12.6 million of cash and $1.47 billion of total debt, producing net debt of $1.45 billion. Enterprise value is therefore materially above the market capitalization of equity. Investors are not buying only current cash generation; they are paying for sustained growth, margin resilience, and the conversion of acquired technology and goodwill into durable cash earnings.

Reverse valuation makes the burden explicit. At the dated market capitalization, the market appears to require operating normalization materially beyond the latest quarter’s 18% revenue growth and 23.8% operating margin. The plausible path is continued double-digit cash-flow growth over several years, sustained margins despite reinvestment, and limited dilution, without a material increase in debt.

That expectation is not impossible, but the burden leaves little room for execution mistakes. A slowdown toward mid-single-digit growth, a fall in retention, higher customer-acquisition costs, or continued weak cash conversion could compress the valuation sharply. The dated price does not provide a Graham-style margin of safety because debt is substantial, tangible book value is negative, and the cash-flow yield is modest relative to the risks.

Ten-Year Cash Flow to Fair Market Value

The starting free cash flow is the normalized SEC cash-flow proxy, while every growth rate, discount rate and terminal rate below is an explicit editorial assumption rather than company guidance. Each annual cash flow is forecast and discounted separately; terminal value is year-ten free cash flow multiplied by one plus terminal growth, divided by discount rate minus terminal growth, and then discounted back ten years. Fair market capitalization equals that explicit ten-year present value plus discounted terminal value and a same-date balance-sheet adjustment when available. If current cash and debt facts do not share one report date, the table shows the adjustment as unavailable and conservatively applies zero. The share count is derived from the dated market capitalization and share price so US shares and foreign ADRs use a consistent traded-security denominator.

In the reverse-DCF, holding the 9% discount rate and 3% terminal growth fixed, and solving only for one constant growth rate rather than using the base-case growth path, the current market capitalization implies roughly 9.6% annual free cash flow growth for ten years. This is a sensitivity framework, not a price target: the terminal-value share shows how strongly each result depends on assumptions beyond the explicit forecast. Negative margin of safety means the current market capitalization exceeds the scenario value.

Five Value-Investing Lenses

Benjamin Graham Lens

The downside floor is the central test. Waystar was profitable in Q2, but the balance sheet has $1.47 billion of total debt, only $12.6 million of cash, and negative tangible book value. Those facts weaken protection against a failed growth assumption or a fall in cash-flow value. Earnings are now substantial enough to be relevant, but the available evidence does not establish a normalized multi-year range through a full industry cycle. The October 26, 2026 price also offers no clear margin of safety: the cash-flow yield is modest while debt remains large. Graham’s discipline therefore points to watching, not treating the shares as protected merely because the business is growing.

Benjamin Franklin Lens

The Franklin lens asks whether scarce capital is compounded wisely and what alternative use deserves consideration. Waystar is generating cash, but it is simultaneously carrying substantial debt, increasing capital spending, paying interest, issuing employee equity, and beginning a large repurchase program. Those choices compete: debt reduction could reduce interest expense and refinancing risk, while reinvestment may protect future earnings, and buybacks can compound per-share value only when shares are bought below conservatively assessed value. The first-half repurchase price of $19.24 looks disciplined relative to the later $28.85 market price, but that comparison is hindsight and does not establish intrinsic value. Opportunity cost argues for measured repurchases rather than enthusiasm.

Warren Buffett Lens

A Buffett-style analysis begins with owner economics. Operating cash flow less total capital expenditure produces a $246.3 million trailing accounting free-cash-flow proxy, but the filings do not separate maintenance from growth capital, and stock-based compensation is an economic cost. The platform could have durable demand because healthcare payment workflows are complex and operationally important, yet switching costs, retention, contract duration, and pricing power are not quantitatively evidenced. Capital allocation is mixed: product investment may strengthen the moat, while debt-funded flexibility and equity compensation can dilute per-share economics. The central question is whether Waystar can turn a growing revenue base into durable per-share cash without repeatedly reinvesting or diluting.

Charlie Munger Lens

Munger’s lens emphasizes incentives, inversion, and cognitive discipline. Management has incentives to emphasize growth and AI-related possibilities, while investors may anchor on a falling or rising share price and assume mission criticality guarantees pricing power. The observable checks are more demanding: net revenue retention, operating cash flow versus net income, diluted shares, acquisition returns, repurchase prices, customer concentration, and cybersecurity impacts. The most likely error is extrapolating recent growth while underestimating reinvestment and debt costs. A disciplined process would demand several years of cash conversion and per-share growth, not merely attractive quarterly revenue. Munger’s standard makes this a case where absence of evidence matters.

Li Lu Lens

Li Lu’s questions are whether this business sits within a durable circle of competence, whether culture compounds trust, and whether permanent loss can be controlled. Healthcare payments are understandable at a high level, but the available evidence lacks the customer, supplier, competitive, and contract detail needed to judge switching costs deeply. The company shows positive operating profit and continued product investment, yet the cybersecurity incident and CFO transition deserve observation. Goodwill and intangibles exceed equity, so impairment or failed acquisition integration could impair capital. Li Lu’s standard would require evidence that the platform becomes more embedded over time and that management earns trust through customer outcomes, not slogans. Here, the business is promising, but cultural durability and permanent-loss control remain partly unresolved.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

The first observable thesis breaker is a sustained deterioration in cash conversion: operating cash flow failing to grow with net income while accounts receivable, deferred costs, or capitalized software continue to absorb cash. The second is weakening commercial durability, demonstrated by declining net revenue retention, shortening contracts, material customer losses, or pricing that prevents margin resilience. The third is leverage stress, visible through materially higher interest expense, covenant pressure, refinancing on unfavorable terms, or debt-funded repurchases and acquisitions. The fourth is cyber or regulatory damage severe enough to disrupt client operations, trigger material costs, or weaken retention after the June 2026 incident.

The most likely wrong assumption is that recent revenue growth will translate into durable, high-margin free-cash-flow growth without a larger reinvestment burden. Waystar’s first-half operating cash flow declined despite higher profit, and capital spending increased. If the required growth plateau is closer to the bear path than the bull path, the current price lacks downside protection.

Opportunity cost is substantial. At a modest cash-flow yield and a leveraged balance sheet, an investor could wait for a better entry price, purchase a less leveraged business with stronger current free-cash-flow conversion, or demand greater evidence that growth is translating into per-share owner earnings. A change in conclusion would require evidence—not merely a lower price—that debt is falling, cash conversion is improving, diluted share growth is controlled, retention remains strong, and capital spending has normalized without sacrificing innovation.

The filing also identifies acquisition integration, client implementation delays, variable selling cycles, healthcare regulation, third-party infrastructure, data privacy, intellectual property, and interest-rate exposure as important uncertainties. These risks are not merely legal boilerplate: each can affect revenue timing, costs, or customer trust.

Investment Conclusion

Waystar is a credible, growing healthcare-payments software company with a visible profit engine and improving quarterly earnings. Its mission-critical workflow position, expanding research investment, and positive operating cash generation support further study. The latest half-year also reveals a less comfortable picture: operating cash flow fell, capital spending increased, debt greatly exceeds cash, intangible assets dominate the balance sheet, and employee equity has diluted shareholders.

At the October 26, 2026 price of $28.85 and a $5.53 billion market capitalization, the shares require sustained operating normalization and strong long-run cash-flow compounding. The market capitalization is substantially above the conservative base valuation, and only the bullish scenario supports it. The conclusion is Overvalued, not because the company lacks quality, but because the price leaves inadequate protection against leverage, reinvestment, execution, and valuation risk.

This analysis is for educational use only and is not individualized investment advice.

This article is for research and educational purposes and does not constitute personalized investment advice.